Get started
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

YMAB chart


Full chart

YMAB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪217.50 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.67 USD
Net income (FY)
‪−29.67 M‬ USD
Revenue (FY)
‪87.69 M‬ USD
Shares float
‪34.45 M‬
Beta (1Y)
1.23

Employees


Employees (FY)
107
Change (1Y)
+7 +7.00%
Revenue / Employee (1Y)
‪819.49 K‬ USD
Net income / Employee (1Y)
‪−277.25 K‬ USD

About Y-mAbs Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael Rossi
Website
ymabs.com
Headquarters
Princeton
Founded
2015
FIGI
BBG00J2DBMZ8
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

YMAB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as YMAB.

Frequently Asked Questions


The current price of YMAB is 4.43 USD — it has decreased by −5.41% in the past 24 hours. Watch Y-mAbs Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Y-mAbs Therapeutics, Inc. stocks are traded under the ticker YMAB.
YMAB stock has fallen by −10.78% compared to the previous week, the month change is a −15.90% fall, over the last year Y-mAbs Therapeutics, Inc. has showed a −73.12% decrease.
We've gathered analysts' opinions on Y-mAbs Therapeutics, Inc. future price: according to them, YMAB price has a max estimate of 26.00 USD and a min estimate of 7.00 USD. Watch YMAB chart and read a more detailed Y-mAbs Therapeutics, Inc. stock forecast: see what analysts think of Y-mAbs Therapeutics, Inc. and suggest that you do with its stocks.
YMAB reached its all-time high on Nov 9, 2020 with the price of 55.22 USD, and its all-time low was 2.70 USD and was reached on Mar 24, 2023. View more price dynamics on YMAB chart.
See other stocks reaching their highest and lowest prices.
YMAB stock is 10.07% volatile and has beta coefficient of 1.23. Track Y-mAbs Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Y-mAbs Therapeutics, Inc. there?
Today Y-mAbs Therapeutics, Inc. has the market capitalization of ‪217.50 M‬, it has decreased by −6.78% over the last week.
Yes, you can track Y-mAbs Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Y-mAbs Therapeutics, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
YMAB earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.12 USD resulting in a −29.17% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about Y-mAbs Therapeutics, Inc. earnings.
Y-mAbs Therapeutics, Inc. revenue for the last quarter amounts to ‪24.50 M‬ USD, despite the estimated figure of ‪26.99 M‬ USD. In the next quarter, revenue is expected to reach ‪19.87 M‬ USD.
YMAB net income for the last quarter is ‪−6.79 M‬ USD, while the quarter before that showed ‪−7.00 M‬ USD of net income which accounts for 2.97% change. Track more Y-mAbs Therapeutics, Inc. financial stats to get the full picture.
No, YMAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 1, 2025, the company has 107 employees. See our rating of the largest employees — is Y-mAbs Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Y-mAbs Therapeutics, Inc. EBITDA is ‪−30.67 M‬ USD, and current EBITDA margin is −33.24%. See more stats in Y-mAbs Therapeutics, Inc. financial statements.
Like other stocks, YMAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Y-mAbs Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Y-mAbs Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Y-mAbs Therapeutics, Inc. stock shows the sell signal. See more of Y-mAbs Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.